Phase 1 Study Poster to be Presented in Osaka, Japan, July 3, 2015 at
4:50 pm Local Time
APPLE Conference Runs July 3-5, 2015
KNOXVILLE, Tenn. -- (Business Wire)
Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, http://www.pvct.com),
a clinical-stage oncology and dermatology biopharmaceutical company
(“Provectus” or the “Company”), announced today that the organizing
committee of the 6th Asia-Pacific Primary Liver Cancer Expert
Meeting has accepted the Company’s abstract "Phase 1 Study of PV-10 for
Chemoablation of Hepatocellular Cancer and Cancer Metastatic to the
Liver", for a poster presentation.
The presentation is scheduled for July 3, 2015, at 4:50-5:50 pm local
time. Making the presentation will be Dr. Sanjiv Agarwala, chief of
medical oncology and hematology at St. Luke’s Cancer Center in
Bethlehem, PA, and professor of medicine at Temple University School of
Medicine in Philadelphia. He served as the principal investigator of the
Phase I clinical trial that produced the data being presented, as well
as the principal investigator in the Phase III clinical trial of PV-10
as a treatment for melanoma which has just begun.
The conference runs July 3-5, 2015, and is being held at The Hyatt
Regency Osaka, in Osaka, Japan. The Company will post the presentation
on its website at www.pvct.com
at the time of the presentation. For more information on the conference,
please visit http://www2.convention.co.jp/apple2015/greeting/index.html.
Provectus will provide more details about the presentation and
conference as they become available.
About APPLE
APPLE 2015 is designed to promote exchanges of international and
regional expertise in the study and management of liver cancer. We are
very privileged to have a number of distinguished international and
local guest faculties who are prominent, world-class leaders in this
field, and have traveled a long way to share and discuss with us the
advances and challenges currently faced in the area of liver cancer.
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals, Inc., specializes in developing oncology
and dermatology therapies. PV-10, its novel investigational drug for
cancer, is designed for injection into solid tumors (intralesional
administration), thereby reducing potential for systemic side effects.
Its oncology focus is on melanoma, breast cancer and cancers of the
liver. The Company has received orphan drug designations from the FDA
for its melanoma and hepatocellular carcinoma indications. PH-10, its
topical investigational drug for dermatology, is undergoing clinical
testing for psoriasis and atopic dermatitis. Provectus has completed
phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of
PH-10 as a topical treatment for atopic dermatitis and psoriasis.
Information about these and the Company’s other clinical trials,
including its current phase 3 study in melanoma, can be found at the NIH
registry, www.clinicaltrials.gov.
For additional information about Provectus, please visit the Company’s
website at www.pvct.com
or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: This release contains "forward-looking
statements" as defined under U.S. federal securities laws. These
statements reflect management's current knowledge, assumptions, beliefs,
estimates, and expectations and express management's current views of
future performance, results, and trends and may be identified by their
use of terms such as "anticipate," "believe," "could," "estimate,"
"expect," "intend," "may," "plan," "predict," "project," "will," and
other similar terms. Forward-looking statements are subject to a number
of risks and uncertainties that could cause our actual results to
materially differ from those described in the forward-looking
statements. Readers should not place undue reliance on forward-looking
statements. Such statements are made as of the date hereof, and we
undertake no obligation to update such statements after this date.
Risks and uncertainties that could cause our actual results to
materially differ from those described in forward-looking statements
include those discussed in our filings with the Securities and Exchange
Commission (including those described in Item 1A of our Annual Report on
Form 10-K for the year ended December 31, 2014) and the following:
-
our determination, based on guidance from the FDA, whether to proceed
with or without a partner with the fully enrolled phase 3 trial of
PV-10 to treat locally advanced cutaneous melanoma and the costs
associated with such a trial if it is necessary to complete (versus
interim data alone);
-
our determination whether to license PV-10, our melanoma drug product
candidate, and other solid tumors such as cancers of the liver, if
such licensure is appropriate considering the timing and structure of
such a license, or to commercialize PV-10 on our own to treat melanoma
and other solid tumors such as cancers of the liver;
-
our ability to license our dermatology drug product candidate, PH-10,
on the basis of our phase 2 atopic dermatitis and psoriasis results,
which are in the process of being further developed in conjunction
with mechanism of action studies; and
-
our ability to raise additional capital if we determine to
commercialize PV-10 and/or PH-10 on our own, although our expectation
is to be acquired by a prospective pharmaceutical or biotech concern
prior to commercialization.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150528006536/en/
Contacts:
Provectus Biopharmaceuticals, Inc.
Peter R. Culpepper, 866-594-5999
#30
CFO, COO
or
Porter, LeVay & Rose, Inc.
Marlon
Nurse, 212-564-4700
DM, SVP – Investor Relations
or
Bill
Gordon, 212-724-6312
Media Relations
Source: Provectus Biopharmaceuticals, Inc.
© 2024 Canjex Publishing Ltd. All rights reserved.